Rhythm Pharmaceuticals Reports Positive Real-World and Phase 3 Data for Setmelanotide in Hypothalamic Obesity
Event summary
- Real-world data from France showed up to 13.4% reduction in mean BMI in pediatric patients with acquired hypothalamic obesity after 9 months of setmelanotide therapy.
- Phase 3 analyses demonstrated significant improvements in multiple cardiometabolic risk indices, including a -0.8 mean change in metabolic syndrome z-BMI score versus placebo.
- Rhythm Pharmaceuticals presented six data sets at the 64th Annual European Society for Paediatric Endocrinology Meeting.
- No new safety concerns were observed, with adverse events consistent with previous Phase 3 trial data.
The big picture
Rhythm Pharmaceuticals' positive data presentations at ESPE 2026 reinforce setmelanotide's potential as a transformative therapy for rare neuroendocrine diseases. The real-world and Phase 3 data strengthen the drug's value proposition in treating pediatric hypothalamic obesity, a market with significant unmet needs. These findings could position Rhythm as a leader in the rare disease space, particularly as it seeks to expand its commercial footprint beyond current approved indications.
What we're watching
- Regulatory Expansion
- Whether Rhythm can leverage these data to expand setmelanotide's approved indications beyond current rare disease applications.
- Commercialization Strategy
- The pace at which Rhythm can translate positive real-world data into broader market adoption for setmelanotide.
- Pipeline Development
- How these findings might influence the development timeline for Rhythm's other MC4R agonists, bivamelagon and RM-718.